Market cap
$1,199 Mln
Revenue (TTM)
$76 Mln
P/E Ratio
--
P/B Ratio
112.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-69 Mln
-
ROE
-10.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
131,880,000
10 Years Aggregate
CFO
$-562.49 Mln
EBITDA
$-618.76 Mln
Net Profit
$-663.48 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CTi Biopharma Corp (CTIC)
| 51.2 | 0.8 | 111.4 | 56.2 | 96.4 | 11.9 | -2.2 |
|
BSE Sensex*
| -11.7 | -2.7 | -8.0 | -8.0 | 6.2 | 7.8 | 10.9 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
CTi Biopharma Corp (CTIC)
| 142.3 | -23.0 | 103.8 | 115.4 | -72.4 | -34.2 | -66.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CTi Biopharma Corp (CTIC)
|
9.1 | 1,198.8 | 75.8 | -77.0 | -71.2 | -- | -- | 112.6 |
| 77.5 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 76.5 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 51.3 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 131.0 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 67.7 | 8,103.6 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24 | 36.9 | |
| 311.7 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 506.7 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 446.2 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 345.6 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
Shareholding Pattern
View DetailsAbout CTi Biopharma Corp (CTIC)
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor... with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Read more
-
Pres, CEO, Interim Chief Medical Officer & Director
Dr. Adam R. Craig M.B.A., M.D., Ph.D.
-
Pres, CEO, Interim Chief Medical Officer & Director
Dr. Adam R. Craig M.B.A., M.D., Ph.D.
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for CTi Biopharma Corp (CTIC)
What is the current share price of CTi Biopharma Corp (CTIC) Today?
The share price of CTi Biopharma Corp (CTIC) is $9.09 (NASDAQ) as of 26-Jun-2023 09:30 EDT. CTi Biopharma Corp (CTIC) has given a return of 96.39% in the last 3 years.
What is the current PB & PE ratio of CTi Biopharma Corp (CTIC)?
Since, TTM earnings of CTi Biopharma Corp (CTIC) is negative, P/E ratio is not available.
The P/B ratio of CTi Biopharma Corp (CTIC) is 112.63 times as on 26-Jun-2023, a 2556 premium to its peers’ median range of 4.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-7.59
|
-39.32
|
|
2021
|
-2.24
|
59.25
|
|
2020
|
-4.32
|
5.71
|
|
2019
|
-2.17
|
5.11
|
|
2018
|
-1.40
|
0.70
|
What is the 52 Week High and Low of CTi Biopharma Corp (CTIC)?
The 52-week high and low of CTi Biopharma Corp (CTIC) are Rs -- and Rs -- as of 29-May-2026.
What is the market cap of CTi Biopharma Corp (CTIC)?
CTi Biopharma Corp (CTIC) has a market capitalisation of $ 1,199 Mln as on 26-Jun-2023. As per SEBI classification, it is a company.
Should I invest in CTi Biopharma Corp (CTIC)?
Before investing in CTi Biopharma Corp (CTIC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.